文献速递MDS 与骨髓增殖性肿瘤浆细胞疾病血栓与止血

VEXAS综合征患者良恶性血液学表现及骨髓特征

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.
PubMed 文献 · Blood Adv · 2021-01-01

该研究报道16例携带UBA1 p.Met41体细胞突变的VEXAS综合征男性患者的血液学表现与骨髓特征,10例合并血液系统疾病,以MDS和浆细胞疾病为主,所有骨髓均见髓系和红系前体细胞胞质空泡,10例发生血栓事件。

要点

  • VEXAS患者应警惕合并MDS、多发性骨髓瘤等血液系统疾病。
  • 骨髓髓系和红系前体细胞胞质空泡是VEXAS的特征性表现。
  • VEXAS患者血栓事件发生率高,需关注静脉血栓栓塞和动脉卒中。

核心结论

  • VEXAS综合征虽以风湿免疫症状起病,但疾病致残和死亡与进展为血液系统疾病相关。
  • 鉴于MDS和多发性骨髓瘤风险增加,监测疾病进展具有重要意义。

研究设计与样本

  • 回顾性分析16例携带UBA1 p.Met41体细胞突变的男性VEXAS综合征患者的临床血液学表现和骨髓特征。

主要发现

  • 10例(10/16)合并血液系统疾病:MDS 6例、多发性骨髓瘤2例、意义未明单克隆丙种球蛋白病2例、单克隆B细胞增多症2例,部分患者存在两种共存克隆过程。
  • 进展为MDS的患者中血小板减少和中性粒细胞减少更常见。
  • 所有骨髓均显示髓系和红系前体细胞胞质空泡,多数骨髓增生活跃伴髓系增生、红系增生低下及不同程度病态造血。
  • 确诊MDS的患者均为较低危(低原始细胞计数、细胞遗传学很好至中等),未观察到白血病进展;10例(10/16)发生血栓事件,包括静脉血栓栓塞和动脉卒中。

关键数值与推荐

  • MDS诊断基于标准预后评分系统,均为较低危:低原始细胞计数、细胞遗传学很好至中等。

临床怎么用

  • 对VEXAS综合征患者应进行血液系统疾病筛查和监测,包括骨髓检查评估MDS和浆细胞疾病。
  • 关注血栓事件风险,必要时进行预防和及时干预。

局限性

  • 样本量较小(16例),可能限制结论的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatic mutations in UBA1 involving hematopoietic stem and myeloid cells have been reported in patients with the newly defined VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. Here, we report clinical hematologic manifestations and unique bone marrow (BM) features in 16 patients with VEXAS. All patients were male and had a history of severe autoinflammatory and rheumatologic manifestations and a somatic UBA1 mutation (p.Met41). Ten patients had hematologic disorders: myelodysplastic syndrome (MDS; 6 of 16), multiple myeloma (2 of 16), monoclonal gammopathy of undetermined significance (2 of 16), and monoclonal B-cell lymphocytosis (2 of 16), and a few of those patients had 2 co-existing clonal processes. Although macrocytic anemia (100%) and lymphopenia (80%) were prevalent in all patients with VEXAS, thrombocytopenia and neutropenia were more common in patients with progression to MDS. All BMs in VEXAS patients had prominent cytoplasmic vacuoles in myeloid and erythroid precursors. In addition, most BMs were hypercellular with myeloid hyperplasia, erythroid hypoplasia, and varying degrees of dysplasia. All patients diagnosed with MDS were lower risk (low blast count, very good to intermediate cytogenetics) according to standard prognostic scoring with no known progression to leukemia. In addition, 10 of 16 patients had thrombotic events, including venous thromboembolism and arterial stroke. Although VEXAS presents symptomatically as a rheumatologic disease, morbidity and mortality are associated with progression to hematologic disease. Given the increased risk of developing MDS and multiple myeloma, surveillance for disease progression is important.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Obiorah IE, Patel BA, Groarke EM, et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv. 2021. PMID: 34427584. doi:10.1182/bloodadvances.2021004976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。